SMAD2 and renal fibrosis: MicroRNA-24-3p has been shown to negatively regulate skeletal muscle fibrosis by targeting smad2 in the TGF-β signaling pathway, cardiac fibrosis by targeting fibroblast growth factor 11 (FGF11), and renal fibrosis by targeting FGF 11 (44, 52, 53).